文献速递垂体与肾上腺疾病

尿液类固醇代谢组学用于EURINE-ACT研究中肾上腺偶发瘤的鉴别诊断:一项前瞻性检测验证研究

Urine steroid metabolomics for the differential diagnosis of adrenal incidentalomas in the EURINE-ACT study: a prospective test validation study.
PubMed 文献 · Lancet Diabetes Endocrinol · 2020-07-23

EURINE-ACT是一项前瞻性多中心检测验证研究,纳入2017例新诊断肾上腺肿块成人患者,以组织病理学和随访为参考标准,评估肿瘤最大径、影像学特征与尿液类固醇代谢组学单独及联合诊断肾上腺皮质癌(ACC)的准确性。结果显示,将平扫CT肿瘤衰减阈值由推荐的10 HU提高至20 HU可在保持敏感性的同时提高特异性;三项检测联合时高危组阳性预测值达76.4%。

要点

  • 平扫CT肿瘤衰减阈值由10 HU提高至20 HU,ACC诊断特异性由64.0%升至80.0%,敏感性维持在99.0%。
  • 尿液类固醇代谢组学提示ACC高风险的阳性预测值为34.6%(95%CI 28.6-41.0)。
  • 肿瘤直径≥4 cm、影像学特征阳性(20 HU阈值)与尿液类固醇代谢组学高危三项联合时阳性预测值为76.4%。

核心结论

  • 作者认为,排除ACC时平扫CT肿瘤衰减阈值应以20 HU取代10 HU;肿瘤直径、影像学特征与尿液类固醇代谢组学三项检测联合策略可提高ACC检出,可能缩短ACC患者至手术的时间,并有助于避免良性肿瘤患者的不必要手术。

研究设计与样本

  • 前瞻性多中心检测验证研究,纳入年龄≥18岁、新诊断肾上腺肿块的成人参与者。
  • 2011年1月17日至2016年7月15日共招募2169例,最终分析纳入来自11个国家14个专科中心的2017例。
  • 以组织病理学及随访检查为参考标准,评估肿瘤最大径(≥4 cm vs <4 cm)、影像学特征(阳性 vs 阴性)与尿液类固醇代谢组学(ACC低、中、高风险)单独及联合的诊断准确性。

主要发现

  • 98例(4.9%)为组织病理学或临床与生化确诊的ACC。
  • 肿瘤直径≥4 cm者488例(24.2%),其中含98例ACC中的96例,阳性预测值19.7%(95%CI 16.2-23.5)。
  • 平扫CT肿瘤衰减阈值由推荐的10 HU提高至20 HU,ACC诊断特异性为80.0%(95%CI 77.9-82.0)vs 64.0%(95%CI 61.4-66.4),敏感性为99.0%(95%CI 94.4-100.0)vs 100.0%(95%CI 96.3-100.0),阳性预测值19.7%(95%CI 16.3-23.5)。
  • 尿液类固醇代谢组学提示ACC高风险的阳性预测值为34.6%(95%CI 28.6-41.0)。
  • 按肿瘤直径、影像学特征阳性(20 HU阈值)、尿液类固醇代谢组学高危顺序联合,106例(5.3%)符合三项条件,阳性预测值76.4%(95%CI 67.2-84.1);70例(3.5%)被归为ACC中等风险,1841例(91.3%)为低风险,阴性预测值99.7%(95%CI 99.4-100.0)。

关键数值与推荐

  • 平扫CT肿瘤衰减阈值应由推荐的10 HU改为20 HU以排除ACC。
  • 肿瘤直径≥4 cm的阳性预测值为19.7%(95%CI 16.2-23.5)。
  • 尿液类固醇代谢组学高风险的阳性预测值为34.6%(95%CI 28.6-41.0)。
  • 三项检测联合高危组阳性预测值为76.4%(95%CI 67.2-84.1),低风险组阴性预测值为99.7%(95%CI 99.4-100.0)。

临床怎么用

  • 作者认为,排除ACC时平扫CT肿瘤衰减阈值应以20 HU取代10 HU。
  • 作者认为,肿瘤直径、影像学特征与尿液类固醇代谢组学三项检测联合策略可提高ACC检出。
  • 作者认为,该联合策略可能缩短ACC患者至手术的时间,并有助于避免良性肿瘤患者的不必要手术。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Cross-sectional imaging regularly results in incidental discovery of adrenal tumours, requiring exclusion of adrenocortical carcinoma (ACC). However, differentiation is hampered by poor specificity of imaging characteristics. We aimed to validate a urine steroid metabolomics approach, using steroid profiling as the diagnostic basis for ACC. METHODS: We did a prospective multicentre study in adult participants (age ≥18 years) with newly diagnosed adrenal masses. We assessed the accuracy of diagnostic imaging strategies based on maximum tumour diameter (≥4 cm vs <4 cm), imaging characteristics (positive vs negative), and urine steroid metabolomics (low, medium, or high risk of ACC), separately and in combination, using a reference standard of histopathology and follow-up investigations. With respect to imaging characteristics, we also assessed the diagnostic utility of increasing the unenhanced CT tumour attenuation threshold from the recommended 10 Hounsfield units (HU) to 20 HU. FINDINGS: Of 2169 participants recruited between Jan 17, 2011, and July 15, 2016, we included 2017 from 14 specialist centres in 11 countries in the final analysis. 98 (4·9%) had histopathologically or clinically and biochemically confirmed ACC. Tumours with diameters of 4 cm or larger were identified in 488 participants (24·2%), including 96 of the 98 with ACC (positive predictive value [PPV] 19·7%, 95% CI 16·2-23·5). For imaging characteristics, increasing the unenhanced CT tumour attenuation threshold to 20 HU from the recommended 10 HU increased specificity for ACC (80·0% [95% CI 77·9-82·0] vs 64·0% [61·4-66.4]) while maintaining sensitivity (99·0% [94·4-100·0] vs 100·0% [96·3-100·0]; PPV 19·7%, 16·3-23·5). A urine steroid metabolomics result indicating high risk of ACC had a PPV of 34·6% (95% CI 28·6-41·0). When the three tests were combined, in the order of tumour diameter, positive imaging characteristics, and urine steroid metabolomics, 106 (5·3%) participants had the result maximum tumour diameter of 4 cm or larger, positive imaging characteristics (with the 20 HU cutoff), and urine steroid metabolomics indicating high risk of ACC, for which the PPV was 76·4% (95% CI 67·2-84·1). 70 (3·5%) were classified as being at moderate risk of ACC and 1841 (91·3%) at low risk (negative predictive value 99·7%, 99·4-100·0). INTERPRETATION: An unenhanced CT tumour attenuation cutoff of 20 HU should replace that of 10 HU for exclusion of ACC. A triple test strategy of tumour diameter, imaging characteristics, and urine steroid metabolomics improves detection of ACC, which could shorten time to surgery for patients with ACC and help to avoid unnecessary surgery in patients with benign tumours. FUNDING: European Commission, UK Medical Research Council, Wellcome Trust, and UK National Institute for Health Research, US National Institutes of Health, the Claire Khan Trust Fund at University Hospitals Birmingham Charities, and the Mayo Clinic Foundation for Medical Education and Research.

来源:Lancet Diabetes Endocrinol,查看原文。版权归原作者所有。

引用

  1. Bancos I, Taylor AE, Chortis V, et al. Urine steroid metabolomics for the differential diagnosis of adrenal incidentalomas in the EURINE-ACT study: a prospective test validation study. Lancet Diabetes Endocrinol. 2020. PMID: 32711725. doi:10.1016/S2213-8587(20)30218-7

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。